Immunotherapeutic agents can effectively activate the immune system, leading to tumor regression, and have improved clinical outcomes in lymphoma patients.349–352 In addition, checkpoint inhibitors combined with CAR-T therapy, epigenetic modulators, radiotherapy, and BTK inhibitors have shown striking efficacy in refractory lymphoma.353–355. The gene discussed is BTK; the disease is lymphoma.